PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Form 8-K August 04, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

August 4, 2016

Pacific Biosciences of California, Inc.

(Exact name of registrant as specified in its charter)

Delaware 001-34899 16-1590339 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.)

1380 Willow Road

Menlo Park, California 94025

(Address of principal executive offices, including zip code)

(650) 521-8000

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02.Results of Operations and Financial Condition.

On August 4, 2016, Pacific Biosciences of California, Inc. announced its financial results for its second fiscal quarter ended June 30, 2016. A copy of the press release containing the announcement is included as Exhibit 99.1 and is incorporated herein by reference.

This information, as well as Exhibit 99.1, is intended to be furnished under Item 2.02 of Form 8-K, "Results of Operations and Financial Condition" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01.	FINANCIAL STATEMENTS AND EXHIBITS.
5	
(d)	Exhibits.
99.1	Press Release dated August 4, 2016 titled "Pacific Biosciences of California, Inc. Announces Second Quarter 2016 Financial Results" (furnished and not filed herewith solely pursuant to Item 2.02).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Susan

Pacific Biosciences of California, Inc.

By: /s/ Susan K. Barnes Susan K. Barnes

Executive Vice President, Chief Financial Officer & Principal Accounting Officer

Date: August 4, 2016

EXHIBIT INDEX

Exhibit No. Description

99.1 Press Release dated August 4, 2016 titled "Pacific Biosciences of California, Inc. Announces Second Quarter 2016 Financial Results" (furnished and not filed herewith solely pursuant to Item 2.02).